<DOC>
	<DOCNO>NCT00477165</DOCNO>
	<brief_summary>Hypotheses : 1 . Primary null hypothesis : The rate clinical response , assess patient-reported global symptom rating `` adequate relief IBS symptom , '' differ non-depressed IBS patient treat SSRI citalopram patient treat placebo . 2 . Secondary null hypothesis : 1 . Changes disease-related quality life , assess IBS-QOL instrument , differ patient treat SSRI citalopram patient treat placebo . 2 . Changes rectosigmoid visceral sensitivity , assess barostat balloon distention , differ patient treat SSRI citalopram patient treat placebo .</brief_summary>
	<brief_title>Citalopram Irritable Bowel Syndrome</brief_title>
	<detailed_description>Irritable bowel syndrome ( IBS ) affect estimate 15 million Americans cost $ 1.7 billion per year . Visceral hypersensitivity present many patient IBS , contribution clinical symptom unclear . Tricyclic antidepressant may beneficial IBS , side effect unacceptable . Because good tolerate , selective serotonin reuptake inhibitor ( SSRIs ) often use treat IBS , efficacy IBS examine controlled study . We propose randomize , placebo-controlled trial SSRI treatment IBS . Non-depressed patient study order ass SSRI effect IBS independent depression . Our specific aim : 1 ) To determine whether SSRI citalopram superior placebo improve clinical symptom , disease-related quality life , tolerance rectal balloon distension ; 2 ) To assess whether symptomatic improvement correlate improvement quality life and/or visceral sensitivity . Subjects fulfill Rome II IBS criterion , normal screen study , depress antidepressant . Global specific symptom , satisfaction rat daily 1-week baseline . Subjects randomize conceal , double-blind fashion citalopram placebo , complete validate IBS-QOL instrument , undergo rectal compliance sensory test barostat . Subjects treated rate symptom satisfaction weekly total 8 week , also daily final week comparison baseline . At study end , subject complete IBS-QOL undergo barostat study . The primary outcome change global symptom rating . Secondary outcome include proportion patient achieve adequate relief correlation symptom , quality life barostat parameter . We estimate detect standardized effect size 0.9 global symptom rating 2-sided α=0.05 β=0.1 , 54 subject need . We plan enroll 60 subject , allow detection odds ratio response ( adequate relief ) 4.5 2-sided α=0.05 β=0.2 . If odds ratio dichotomous outcome small , study provide pilot data large trial . Clinical symptom expect fluctuate . Even citalopram superior placebo , prospectively collect data illuminate relationship symptoms visceral sensitivity , placebo effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inclusion criterion : 1 . Fulfilling Rome II IBS definition ; ( 21 ) 2 . Age ≥18 yr able give inform consent ; 3 . Normal sigmoidoscopy , colonoscopy barium enema within 5 year , normal complete blood count thyroid study , negative stool ovum parasite exam patient diarrhea . ( 1 ) Exclusion criterion : 1 . Current psychiatric diagnosis active treatment antidepressant ; 2 . Pregnancy ; 3 . Major systemic illness , illness could explain IBSlike symptom ; 4 . Active IBS therapy fiber loperamide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>IBS</keyword>
	<keyword>Serotonin-reuptake inhibitor</keyword>
	<keyword>SSRI</keyword>
	<keyword>Visceral sensitivity</keyword>
	<keyword>Barostat</keyword>
	<keyword>Quality life</keyword>
	<keyword>Depression</keyword>
</DOC>